APA

Markova S. M., De Marco T., Bendjilali N., Kobashigawa E. A., Mefford J., Sodhi J., Le H., Zhang C., Halladay J., Rettie A. E., Khojasteh C., McGlothlin D., Wu A. H. B., Hsueh W., Witte J. S., Schwartz J. B. & Kroetz D. L. (20140113). Association of CYP2C9*2 with bosentan-induced liver injury. : Clinical pharmacology and therapeutics.

Chicago

Markova S M, De Marco T, Bendjilali N, Kobashigawa E A, Mefford J, Sodhi J, Le H, Zhang C, Halladay J, Rettie A E, Khojasteh C, McGlothlin D, Wu A H B, Hsueh W-C, Witte J S, Schwartz J B and Kroetz D L. 20140113. Association of CYP2C9*2 with bosentan-induced liver injury. : Clinical pharmacology and therapeutics.

Harvard

Markova S. M., De Marco T., Bendjilali N., Kobashigawa E. A., Mefford J., Sodhi J., Le H., Zhang C., Halladay J., Rettie A. E., Khojasteh C., McGlothlin D., Wu A. H. B., Hsueh W., Witte J. S., Schwartz J. B. and Kroetz D. L. (20140113). Association of CYP2C9*2 with bosentan-induced liver injury. : Clinical pharmacology and therapeutics.

MLA

Markova S M, De Marco T, Bendjilali N, Kobashigawa E A, Mefford J, Sodhi J, Le H, Zhang C, Halladay J, Rettie A E, Khojasteh C, McGlothlin D, Wu A H B, Hsueh W-C, Witte J S, Schwartz J B and Kroetz D L. Association of CYP2C9*2 with bosentan-induced liver injury. : Clinical pharmacology and therapeutics. 20140113.